Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 836

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 836
---
 its existing capital resources, including anticipated payment of the Warrant Exercise Notes (as defined and described in Note 15 below), will be sufficient to fund the Company’s planned future operations into the late fourth quarter of 2025. F-80

TUHURA BIOSCIENCES, INC AND SUBSIDIARIES Notes to the consolidated financial statements For the years ended December 31, 2024, and 2023 The Company expects to raise cash through the sale of preferred shares, common shares, debt issuances, obtaining grants, or commercial partnerships. However, there can be no assurance that any fundraising will be achieved or on commercially reasonable terms, if at all. As such, there is substantial doubt about the Company’s ability to continue as a going concern for the next 12 months from date that the financial statements were available to be issued.

Note 4-Netloss per share

Basic and diluted net loss per share attributable to common stockholders was calculated as follows:

| Numerator:                                                                 |     | Years Ended December 31, 
 2024                     |             |   |     | 2023 |             |   |
|:---------------------------------------------------------------------------|:----|:-------------------------|------------:|:--|:----|:-----|------------:|:--|
| Net loss attributable to common stockholders                               |     | $                        | (22,649,572 | ) |     | $    | (29,316,826 | ) |
| Denominator:                                                               |     |                          |             |   |     |      |             |   |
| Weighted-average common shares outstanding - basic and diluted             |     |                          |  18,662,690 |   |     |      |  11,889,193 |   |
| Net loss per share attributable to common shareholders - basic and diluted |     | $                        |       (1.21 | ) |     | $    |       (2.47 | ) |

Common stock warrants in the amount of 279,029issued to our financial advisor, H.C. Wainwright & Co., LLC, were not outstanding as common shares as of December 31, 2024, however included in the weighted-average common shares outstanding - basic and diluted as if they were considered outstanding.

The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate